Insmed (INSM) Income from Continuing Operations (2010 - 2026)
Insmed (INSM) recorded quarterly Income from Continuing Operations of 163563000.0 in Q1 2026, up 50.21% quarter-over-quarter from 328485000.0 in Q4 2025, and up 36.25% on a YoY basis from 120045890.84 in Q1 2025.
Insmed (INSM) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Insmed's Income from Continuing Operations history runs 17 years deep, the most recent figure standing at 163563000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 36.25% year-over-year to 163563000.0; the TTM figure through Mar 2026 stood at 1183735000.0 (down 16.82% YoY), while the FY2025 annual figure was 1276775000.0, down 39.73% from the prior year.
- Income from Continuing Operations was 163563000.0 for Q1 2026 at Insmed, up from 328485000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 94621000.0 in Q1 2022 to a low of 370001000.0 in Q3 2025.
- Historically, Income from Continuing Operations has averaged 210893352.94 across 5 years, with a median of 186063000.0 in 2023.
- The sharpest annual moves came in 2023 and 2026: Income from Continuing Operations sank 155.96% in 2023, then jumped 36.25% in 2026.
- A 5-year view of Income from Continuing Operations shows it stood at 160081000.0 in 2022, then retreated by 16.23% to 186063000.0 in 2023, then fell by 26.61% to 235582000.0 in 2024, then slumped by 39.44% to 328485000.0 in 2025, then surged by 50.21% to 163563000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 163563000.0 (Q1 2026), 328485000.0 (Q4 2025), and 370001000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | -3.40 Mn |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | -56.48 Mn |
| 10 | Insmed | 21.32 Bn | 20.09 Bn | 258.54 Mn | -163.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -163.56 Mn |
| Dec 31, 2025 | -328.49 Mn |
| Sep 30, 2025 | -370.00 Mn |
| Jun 30, 2025 | -321.69 Mn |
| Mar 31, 2025 | -256.57 Mn |
| Dec 31, 2024 | -235.58 Mn |
| Sep 30, 2024 | -220.51 Mn |
| Jun 30, 2024 | -300.61 Mn |
| Mar 31, 2024 | -157.09 Mn |
| Dec 31, 2023 | -186.06 Mn |
| Sep 30, 2023 | -158.93 Mn |
| Jun 30, 2023 | -244.81 Mn |
| Mar 31, 2023 | -159.76 Mn |
| Dec 31, 2022 | -160.08 Mn |
| Sep 30, 2022 | -131.17 Mn |
| Jun 30, 2022 | -95.65 Mn |
| Mar 31, 2022 | -94.62 Mn |
| Dec 31, 2021 | -112.94 Mn |
| Sep 30, 2021 | -112.71 Mn |
| Jun 30, 2021 | -117.30 Mn |